Objective To compare the clinical effect of recombinant human follicle stimulating hormone,recombinant human luteinizing hormone and urinary gonadotropin in long protocol ovulation induction in follicular phase.Methods The clinical data of 140 patients indergoing in vitro fertilization(IVF)with long follicular phase ovulation induction in Ganzhou Maternal and Child Health Hospital from May 2018 to December 2019 were retrospectively analyzed.According to the different treatment schemes,they were divided into group A(73 cases)and group B(67 cases).Group A was treated with recombinant human luteinizing hormone combined with recombinant human follicle stimulating hormone,and group B was treated with urinary gonadotropin combined with recombinant human follicle stimulating hormone.The clinical observation indexes,treatment outcome and physiological indexes of the two groups were compared.Results There was no significant difference in the total amount of gonadotropin(Gn),days of Gn use,normal fertilization rate,high-quality embryo rate,blastocyst formation rate and pregnancy rate between the two groups(P＞0.05).There was no significant difference in endometrial thickness,estradiol,progesterone and luteinizing hormone(LH)levels between the two groups before treatment(P＞0.05).The levels of endometrial thickness,LH,progesterone and estradiol of the two groups after treatment were higher than those before treatment,and the differences were statistically significant(P＜0.05).Conclusion For ovulation induction patients with long follicular period regimen,recombinant human follicle stimulating hormone combined with recombinant human luteinizing hormone or recombinant human follicle stimulating hormone combined with urinary gonadotropin can effectively assist pregnancy and have clinical application value.The urinary gonadotrophin is cheap,and can reduces the amount of recombinant human follicle-stimulating hormone,and reduces the economic burden of patients,so it can be popularized in clinical application.